In the remote town of Piñas, nestled in the Andes mountains of southern Ecuador, an intriguing phenomenon has captured the attention of medical researchers. The town's population of 8,000 includes an unusually high number of individuals living with Laron syndrome, a rare genetic condition that halts growth at around 1.2 meters (3.9 feet). This unique concentration of Laron syndrome cases has sparked curiosity and hope, as scientists believe it may hold the key to preventing cancer and other diseases.
María Luísa Romero and her twin sister, María del Cisne, both live with Laron syndrome. They describe the challenges of their condition but also the strength they find in each other. "We're always there for each other, supporting and defending one another," María Luísa says, highlighting the importance of community and support systems.
What makes Laron syndrome particularly fascinating is its potential to unlock new treatments for cancer. Individuals with this syndrome have a lower incidence of diseases like cancer and diabetes compared to the general population. Endocrinologist Dr. Jaime Guevara, who has studied Laron syndrome for 40 years, explains, "The idea is to replicate, through a drug or diet, the unique biological processes in Laron syndrome patients for those without the syndrome. It's an incredible opportunity."
Laron syndrome, also known as growth hormone insensitivity, occurs when the body cannot utilize the growth hormone it produces. The genetic mutation was first identified by paediatrician Zvi Laron while treating patients in Israel over 60 years ago. Today, the majority of known cases are found in the southern Ecuadorean provinces of El Oro and Loja.
Prof. Laron believes the mutation originated thousands of years ago in Indonesia and spread westward along ancient merchant routes. Sephardic Jews with the mutation later migrated to different continents, including the Americas, leading to the high concentration of cases in Ecuador. According to Prof. Laron, the mutation was carried by individuals who settled in isolated areas, and generations of inbreeding within these communities resulted in a particularly high incidence of Laron syndrome.
Living with others who share the same condition has been a source of comfort for the twins. "Knowing we're not alone makes a huge difference. We can share our experiences, both good and bad, and support each other through the daily challenges," María del Cisne explains.
However, when the twins moved away to study, they faced new challenges. "People had never seen anyone like us before, and the stares and pointing were difficult to handle. It was a strange experience," María Luísa recalls.
Prof. Laron is set to publish a comprehensive research paper documenting all known cases of the mutation, identified between 1966 and 2025. This paper will provide an unprecedented understanding of the exact number of Laron syndrome patients and the various growth hormone receptor defects associated with the condition.
The potential for Laron syndrome to contribute to scientific advancements offers a sense of purpose and hope to those living with the condition. The twins, who have participated in Dr. Guevara's major study, initially believed they were immune to cancer and other diseases. However, María del Cisne's diagnosis of colon cancer two years ago served as a wake-up call.
"It made us realize that we weren't invincible. We needed to take care of ourselves, exercise, and watch our diet. It was a valuable lesson," the sisters reflect.
Laron syndrome is a recessive condition, meaning individuals must inherit the gene from both parents to present symptoms. The twins each have a child without Laron syndrome, who, at eight years old, are already taller than their mothers.
For those born with Laron syndrome, there is a glimmer of hope in the form of a drug called Increlex. This medication, developed 15 years ago, can increase height if administered during growth spurts. However, accessing the drug is challenging, and it has limitations. It can only be given to children between two and 18 years old and may cause serious side effects. The cost is also a significant barrier, with each bottle costing over $800, and a child with Laron syndrome requiring at least three bottles per month.
Mayra Loaiza, a resident of Piñas, is one of many struggling to obtain the drug for her two-year-old daughter, Camila. Mayra worries about the potential impact on Camila's growth and hopes the drug will allow her daughter to live a normal life without facing discrimination due to her size.
The twins, now 40, missed the window for taking Increlex during their youth. They wonder about the possibilities it could have opened up for them but have learned to accept their short stature. "We've come to terms with ourselves, but the treatment would have spared us a lot of heartache," María Luísa says. "I've accepted myself as I am, and I'm grateful for who I am."
The story of Laron syndrome and its potential impact on cancer prevention highlights the intricate relationship between genetics, environment, and human resilience. It serves as a reminder of the importance of community, support, and the ongoing pursuit of scientific knowledge to improve human health and well-being.
